This conference will explore the latest research into the biology, optimization and applications of antibodies. Case studies will be presented that report on the current status of several antibodies which have made it to the clinic.
The
Antibody Binding Site-Predicting Specificity through Structure
Design and Validation of Biased
Antibody Repertoires
Crystal Structures of an Anti-ssDNA Fab: Polyspecificity through Structural
Plasticity
Use of Anti-Epitope Tag Antibody Microarrays to Display and Screen Recombinant
Single Chain Antibody (scFv) Libraries
Antibody
Potency Optimization
The Symplex™ Technology for
Direct Cloning and Screening of Therapeutic Antibodies from Human Donors while
Maintaining the Original Pairing of Heavy and Light Chains
Increasing Effector Function through Glycosylation Design
A Novel Antibody Display System for Full Length IgGs
Oligoclonics: Mixtures of Recombinant Human Antibodies Produced by Clonal Cell
Lines
Antibody-Like
Fragments
High-Throughput Parallel
Expression and Purification of scFv, Fab and IgG: How Sample Preparation
Accelerates Antibody Drug Development
Affilin - Alternative Binding Proteins and Their Use
Engineered Fc Case Study: Extending the Serum Half-Lives of Antibodies
Antibody
Therapeutics and Diagnostics: Selection, Optimization, Application: Part I
Selection of Highly Stable Human
Antibody Fragments for Compartmental Therapeutic Approaches
Rapid Development of
Anti-Chemotactic Monoclonal Antibodies
Antibody
Therapeutics and Diagnostics: Selection, Optimization, Application: Part II
Engineered Antibodies and
Antibody-Based Fusion Proteins as HIV-1 Inhibitors
Passive Immunization of Pigs with Llama Single-Domain Antibody Fragments to
Prevent Foot-and-Mouth Disease
Novel Molecular Evolution Strategies for Selection of High-Value Clinical
Reagents, Targeting Cancers and Emerging Infectious Diseases
Relative Importance of Isotype Switching and Somatic Hypermutation on Antibody
Engineering
Cell-based Based Selection of Internalizing Antagonistic Human Antibodies to
Flt-3 for Anti-Leukemia Therapy
ANTIBODIES AS DRUGS: CURRENT STATUS
TRAIL, Anthrax and Blyss Programs
Ultra-Potent Antibody against Respiratory Syncytial Virus: Effects of Binding
Kinetics and Binding Valence on Viral Neutralization
Targeting Connective Tissue Growth Factor (CTGF): Lung Fibrosis, Nephropathy and
Cancer
Scientific Advisory Board
Dr. Hennie Hoogenboom, Merus BV
Dr. Peter Hudson, CSIRO-Australia
Dr. Lutz Jermutus, Cambridge Antibody Technology Ltd.
Dr. Sachdev Sidhu, Genentech, Inc.
Dr. Arne Skerra, Technical University Munich
